References
Rustgi, A.K. N. Engl. J. Med. 331, 1694–1702 (1994).
Bannayan, G.A. Arch. PathoL. 92, 1–5 (1971).
Gorlin, R.J., Cohen, M.M., Condon, L.M. & Burke, B.A. Am. J. Med. Genet. 44, 307–314 (1992).
Zonana, J., Rimoin, D.L. & Davis, D.C. J. Pediatr. 89, 600–603 (1976).
Higginbottom, M.C. & Schultz, P. Pediatrics 69, 632–634 (1982).
Eng, C. J. Genet. Counsel. 6, 181–191 (1997).
Hemminki, A. et al. Nature Genet. 15, 87–90 (1997).
Jacoby, R.F. et al. Gastroenterology 112, 1398–1403 (1997).
Nelen, M.R. et al. Nature Genet. 13, 114–116 (1996).
Myers, M.P. et al. Proc. Natl. Acad. Sci. USA (in the press).
Li, J. et al. Science 275, 1943–1947 (1997).
Steck, P.A. et al. Nature Genet. 15, 356–362 (1997).
Liaw, D. et al. Nature Genet. 16, 64–67 (1997).
Eng, C. et al. JAMA 276, 1575–1579 (1996).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Marsh, D., Dahia, P., Zheng, Z. et al. Germline mutations in PTEN are present in Bannayan-Zonana syndrome. Nat Genet 16, 333–334 (1997). https://doi.org/10.1038/ng0897-333
Issue Date:
DOI: https://doi.org/10.1038/ng0897-333
- Springer Nature America, Inc.
This article is cited by
-
E3 ubiquitin ligase RNF126 affects bladder cancer progression through regulation of PTEN stability
Cell Death & Disease (2021)
-
Invasive apocrine carcinoma of the breast: clinicopathologic features and comprehensive genomic profiling of 18 pure triple-negative apocrine carcinomas
Modern Pathology (2020)
-
The functions and regulation of the PTEN tumour suppressor: new modes and prospects
Nature Reviews Molecular Cell Biology (2018)
-
In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS)
neurogenetics (2018)
-
Clinical and molecular diagnosis, screening and management of Beckwith–Wiedemann syndrome: an international consensus statement
Nature Reviews Endocrinology (2018)